{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:50:55Z","timestamp":1791543055774,"version":"4.3.4"},"reference-count":95,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disord Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Progressive supranuclear palsy is a rare and rapidly progressive neurodegenerative syndrome. Clinical manifestations are heterogeneous and include Parkinsonism, postural instability, oculomotor dysfunction and cognitive impairment, with 80% of patients progressing to dementia within 3\u2009years. Cognitive impairment is consistently associated with poorer outcomes independent of motor function, including increased mortality, morbidity, caregiver burden and healthcare utilization. The prototypic cognitive phenotype of PSP demonstrates marked deficits in executive functions and slowed processing speed accompanied by neuropsychiatric symptoms. Cross\u2010sectionally, these deficits are readily detected across a range of cognitive screening tools and more comprehensive neuropsychological batteries. Brief bedside assessments, such as the Frontal Assessment Battery, are highly effective at differentiating PSP from idiopathic Parkinson's disease soon after motor symptom onset. However, as the field increasingly moves toward disease\u2010modifying trials that include cognitive outcome measures the purpose of cognitive assessment shifts; from supporting a clinical diagnosis, to measuring progression thereafter. The sensitivity to change of commonly used cognitive outcome measures is therefore a priority. In this narrative review we evaluate longitudinal cognitive assessment in PSP. We specifically focus on the unique challenges of cognitive assessment in this patient group and propose measurement priorities for future development.<\/jats:p>","DOI":"10.1002\/mdc3.70847","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:01:07Z","timestamp":1791540067000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Cognitive Function in Progressive Supranuclear Palsy\u2014A Review of the Evidence for Progression"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-1130","authenticated-orcid":false,"given":"Timothy P.","family":"Siejka","sequence":"first","affiliation":[{"name":"Monash University  Melbourne Australia"},{"name":"Alfred Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4283-1182","authenticated-orcid":false,"given":"Kelly L.","family":"Bertram","sequence":"additional","affiliation":[{"name":"Monash University  Melbourne Australia"},{"name":"Alfred Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-8727","authenticated-orcid":false,"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[{"name":"Monash University  Melbourne Australia"},{"name":"Alfred Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Darby","sequence":"additional","affiliation":[{"name":"Monash University  Melbourne Australia"},{"name":"Alfred Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-2862","authenticated-orcid":false,"given":"Amy","family":"Brodtmann","sequence":"additional","affiliation":[{"name":"Monash University  Melbourne Australia"},{"name":"Alfred Health  Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"3","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(09)70042-0","article-title":"Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges","volume":"8","author":"Williams DR","year":"2009","journal-title":"Lancet Neurol"},{"key":"e_1_2_10_3_1","first-page":"25","article-title":"Progressive supranuclear palsy","volume":"10","author":"Steele J","year":"1963","journal-title":"Trans Am Neurol Assoc"},{"issue":"12","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.557","article-title":"Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade","volume":"6","author":"Takigawa H","year":"2016","journal-title":"Brain Behav"},{"issue":"5","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/mdc3.13489","article-title":"Systematic review of prevalence studies of progressive supranuclear palsy and corticobasal syndrome","volume":"9","author":"Swallow DMA","year":"2022","journal-title":"Mov Disord Clin Pract"},{"issue":"6","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/mds.28011","article-title":"Copathology in progressive supranuclear palsy: does it matter?","volume":"35","author":"Jecmenica Lukic M","year":"2020","journal-title":"Mov Disord"},{"key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jns.2017.09.043","article-title":"Natural history and predictors of survival in progressive supranuclear palsy","volume":"382","author":"Cosseddu M","year":"2017","journal-title":"J Neurol Sci"},{"issue":"3","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab206","article-title":"Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants","volume":"3","author":"Street D","year":"2021","journal-title":"Brain Commun"},{"issue":"6","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger GU","year":"2017","journal-title":"Mov Disord"},{"issue":"8","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/mds.27619","article-title":"Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy","volume":"34","author":"Ali F","year":"2019","journal-title":"Mov Disord"},{"issue":"6","key":"e_1_2_10_11_1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000479110","article-title":"Mild cognitive impairment and progression to dementia in progressive supranuclear palsy","volume":"17","author":"Pilotto A","year":"2017","journal-title":"Neurodegener Dis"},{"issue":"4","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/mdc3.14315","article-title":"Rapid cognitive deterioration in progressive supranuclear palsy: a 1\u2010year follow\u2010up study","volume":"12","author":"Li XY","year":"2025","journal-title":"Mov Disord Clin Pract"},{"issue":"2","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jnnp.37.2.121","article-title":"The \u2018subcortical dementia\u2019 of progressive supranuclear palsy","volume":"37","author":"Albert ML","year":"1974","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/mds.27198","article-title":"Cognitive impairment in progressive supranuclear palsy is associated with tau burden","volume":"32","author":"Koga S","year":"2017","journal-title":"Mov Disord"},{"key":"e_1_2_10_15_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120718","article-title":"Neuropathological analysis of cognitive impairment in progressive supranuclear palsy","volume":"451","author":"Sakuwa M","year":"2023","journal-title":"J Neurol Sci"},{"key":"e_1_2_10_16_1","article-title":"Linking PI\u20102620 tau\u2010PET, fluid biomarkers, MRI, and cognition to advance diagnostics for progressive supranuclear palsy","author":"Dilcher R","year":"2024","journal-title":"medRxiv"},{"issue":"5","key":"e_1_2_10_17_1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1136\/jnnp-2016-314956","article-title":"Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta\u2010analysis","volume":"88","author":"Glasmacher SA","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209793","article-title":"Predictors of care home admission and survival rate in patients with syndromes associated with frontotemporal lobar degeneration in Europe","volume":"103","author":"Borroni B","year":"2024","journal-title":"Neurology"},{"issue":"7","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mds.27034","article-title":"Which ante mortem clinical features predict progressive supranuclear palsy pathology?","volume":"32","author":"Respondek G","year":"2017","journal-title":"Mov Disord"},{"issue":"4","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.parkreldis.2013.01.002","article-title":"Disability in atypical parkinsonian syndromes is more dependent on memory dysfunction than motor symptoms","volume":"19","author":"Cushing N","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/mds.25113","article-title":"Cognitive testing in the diagnosis of parkinsonian disorders: a critical appraisal of the literature","volume":"27","author":"Lee W","year":"2012","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/mds.25872","article-title":"Cognition in corticobasal syndrome and progressive supranuclear palsy: a review","volume":"29","author":"Burrell JR","year":"2014","journal-title":"Mov Disord"},{"issue":"2","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/mdc3.12130","article-title":"Scales to assess clinical features of progressive supranuclear palsy: MDS task force report","volume":"2","author":"Hall DA","year":"2015","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1176\/appi.neuropsych.17010012","article-title":"Use of the neuropsychiatric inventory to characterize the course of neuropsychiatric symptoms in progressive supranuclear palsy","volume":"30","author":"Jecmenica\u2010Lukic M","year":"2018","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"e_1_2_10_25_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.25843","article-title":"Rate of decline in progressive supranuclear palsy","volume":"29","author":"Litvan I","year":"2014","journal-title":"Mov Disord"},{"issue":"9","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074486","article-title":"A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy","volume":"8","author":"Ghosh BC","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/mds.25437","article-title":"Modeling trajectories of regional volume loss in progressive supranuclear palsy","volume":"28","author":"Josephs KA","year":"2013","journal-title":"Mov Disord"},{"issue":"5","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/mds.26580","article-title":"Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy","volume":"31","author":"Stamelou M","year":"2016","journal-title":"Mov Disord"},{"issue":"8","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s00415-016-8169-1","article-title":"PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy","volume":"263","author":"Nuebling G","year":"2016","journal-title":"J Neurol"},{"issue":"1","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13195-025-01775-x","article-title":"Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials","volume":"17","author":"Harris GA","year":"2025","journal-title":"Alzheimer's Res Ther"},{"issue":"1","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41467-024-55442-0","article-title":"A 15\u2010item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance","volume":"16","author":"Dam T","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.47.1.1","article-title":"Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele\u2010Richardson\u2010Olszewski syndrome): report of the NINDS\u2010SPSP international workshop","volume":"47","author":"Litvan I","year":"1996","journal-title":"Neurology"},{"issue":"5","key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1136\/practneurol-2020-002794","article-title":"Progressive supranuclear palsy: diagnosis and management","volume":"21","author":"Rowe JB","year":"2021","journal-title":"Pract Neurol"},{"issue":"4","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/13554790590962933","article-title":"Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing","volume":"11","author":"Paviour DC","year":"2005","journal-title":"Neurocase"},{"issue":"10","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.parkreldis.2015.08.006","article-title":"The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias","volume":"21","author":"Stamelou M","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"e_1_2_10_36_1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","article-title":"Neuropathology of frontotemporal lobar degeneration\u2010tau (FTLD\u2010tau)","volume":"45","author":"Dickson DW","year":"2011","journal-title":"J Mol Neurosci"},{"issue":"2","key":"e_1_2_10_37_1","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcad042","article-title":"Verbal fluency tests assess global cognitive status but have limited diagnostic differentiation: evidence from a large\u2010scale examination of six neurodegenerative diseases","volume":"5","author":"Henderson SK","year":"2023","journal-title":"Brain Commun"},{"issue":"2","key":"e_1_2_10_38_1","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/JAD-170743","article-title":"Aphasia in progressive supranuclear palsy: As severe as progressive non\u2010fluent aphasia","volume":"61","author":"Burrell JR","year":"2018","journal-title":"J Alzheimer's Dis"},{"issue":"3","key":"e_1_2_10_39_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s00415-019-09463-1","article-title":"Language impairment in progressive supranuclear palsy and corticobasal syndrome","volume":"268","author":"Peterson KA","year":"2021","journal-title":"J Neurol"},{"issue":"3","key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaneurol.2019.4347","article-title":"Diagnosis across the Spectrum of progressive supranuclear palsy and corticobasal syndrome","volume":"77","author":"Jabbari E","year":"2020","journal-title":"JAMA Neurol"},{"issue":"14","key":"e_1_2_10_41_1","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/mds.26054","article-title":"The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases","volume":"29","author":"Respondek G","year":"2014","journal-title":"Mov Disord"},{"issue":"6","key":"e_1_2_10_42_1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/brain\/awh488","article-title":"Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP\u2010parkinsonism","volume":"128","author":"Williams DR","year":"2005","journal-title":"Brain"},{"issue":"2","key":"e_1_2_10_43_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00702-023-02591-z","article-title":"Clinical, cognitive, and morphometric profiles of progressive supranuclear palsy phenotypes","volume":"130","author":"Campagnolo M","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"e_1_2_10_44_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105290","article-title":"Longitudinal clinical decline and baseline predictors in progressive supranuclear palsy","volume":"107","author":"Pavone C","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"7","key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-019-09324-x","article-title":"Motor, cognitive and behavioral differences in MDS PSP phenotypes","volume":"266","author":"Picillo M","year":"2019","journal-title":"J Neurol"},{"issue":"1","key":"e_1_2_10_46_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2024-000946","article-title":"Cognitive impairment in PSP compared with PD: assessment by clinical subtype and longitudinal change","volume":"7","author":"Tsuboi T","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"e_1_2_10_47_1","article-title":"Whole\u2010brain atrophy rate in idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy","volume":"2016","author":"Guevara C","year":"2016","journal-title":"Parkinsons Dis"},{"issue":"4","key":"e_1_2_10_48_1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/mds.25824","article-title":"A phase 2 trial of the GSK\u20103 inhibitor tideglusib in progressive supranuclear palsy","volume":"29","author":"Tolosa E","year":"2014","journal-title":"Mov Disord"},{"issue":"8","key":"e_1_2_10_49_1","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti\u2010tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo\u2010controlled trial","volume":"27","author":"Dam T","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"e_1_2_10_50_1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41531-023-00565-2","article-title":"Fiber\u2010specific micro\u2010 and macroscopic white matter alterations in progressive supranuclear palsy and corticobasal syndrome","volume":"9","author":"Uchida W","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"e_1_2_10_51_1","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/mds.29421","article-title":"Longitudinal synaptic loss in primary tauopathies: an in vivo [11C]UCB\u2010J positron emission tomography study","volume":"38","author":"Holland N","year":"2023","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_2_10_52_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000214","article-title":"Longitudinal changes of early motor and cognitive symptoms in progressive supranuclear palsy: the OxQUIP study","volume":"4","author":"Pereira MF","year":"2022","journal-title":"BMJ Neurol Open"},{"issue":"8","key":"e_1_2_10_53_1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/mdc3.13334","article-title":"Strategy adherence: a specific and rapidly progressive deficit in progressive supranuclear palsy","volume":"8","author":"Brzezicki MA","year":"2021","journal-title":"Mov Disord Clin Pract"},{"issue":"11","key":"e_1_2_10_54_1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00702-019-02065-1","article-title":"Characteristics and progression of cognitive deficits in progressive supranuclear palsy vs. multiple system atrophy and Parkinson's disease","volume":"126","author":"Fiorenzato E","year":"2019","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"e_1_2_10_55_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000266","article-title":"CoQ10 in progressive supranuclear palsy: a randomized, placebo\u2010controlled, double\u2010blind trial","volume":"3","author":"Apetauerova D","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"e_1_2_10_56_1","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/jnnp-2012-303618","article-title":"The Addenbrooke's cognitive examination for the differential diagnosis and longitudinal assessment of patients with parkinsonian disorders","volume":"84","author":"Rittman T","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"e_1_2_10_57_1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/mdc3.14348","article-title":"A short cognitive and neuropsychiatric assessment scale for progressive supranuclear palsy","volume":"12","author":"Porsche S","year":"2025","journal-title":"Mov Disord Clin Pract"},{"issue":"8","key":"e_1_2_10_58_1","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/brain\/awad105","article-title":"Progression of atypical parkinsonian syndromes: PROSPECT\u2010M\u2010UK study implications for clinical trials","volume":"146","author":"Street D","year":"2023","journal-title":"Brain"},{"issue":"4","key":"e_1_2_10_59_1","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/mds.27964","article-title":"The progressive supranuclear palsy clinical deficits scale","volume":"35","author":"Piot I","year":"2020","journal-title":"Mov Disord"},{"key":"e_1_2_10_60_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1501206","article-title":"Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy","volume":"15","author":"Ibrahim V","year":"2024","journal-title":"Front Neurol"},{"issue":"3","key":"e_1_2_10_61_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000351671","article-title":"Validation of the Addenbrooke's cognitive examination III in frontotemporal dementia and Alzheimer's disease","volume":"36","author":"Hsieh S","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"7","key":"e_1_2_10_62_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","article-title":"Davunetide in patients with progressive supranuclear palsy: a randomised, double\u2010blind, placebo\u2010controlled phase 2\/3 trial","volume":"13","author":"Boxer AL","year":"2014","journal-title":"Lancet Neurol"},{"key":"e_1_2_10_63_1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.parkreldis.2016.04.014","article-title":"Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials","volume":"28","author":"Bang J","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_10_64_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.parkreldis.2021.10.007","article-title":"Development of a cognitive composite for measuring change in progressive supranuclear palsy","volume":"92","author":"Jaeger J","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_10_65_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.parkreldis.2016.04.006","article-title":"Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy","volume":"28","author":"Tsai RM","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_10_66_1","volume-title":"Color Trails test: PAR","author":"D'Elia L","year":"1996"},{"issue":"8","key":"e_1_2_10_67_1","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awq158","article-title":"Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy","volume":"133","author":"Brown RG","year":"2010","journal-title":"Brain"},{"issue":"1","key":"e_1_2_10_68_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/brain\/awn291","article-title":"Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study","volume":"132","author":"Bensimon G","year":"2009","journal-title":"Brain"},{"key":"e_1_2_10_69_1","volume-title":"Practitioner's Guide to Evaluating Change with Neuropsychological Assessment Instruments","author":"McCaffrey RJ","year":"2000"},{"issue":"3","key":"e_1_2_10_70_1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/13854046.2019.1670865","article-title":"Cognitive decline on the repeatable battery for the assessment of neuropsychological status in progressive supranuclear palsy","volume":"34","author":"Duff K","year":"2020","journal-title":"Clin Neuropsychol"},{"issue":"4","key":"e_1_2_10_71_1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/13854046.2012.680913","article-title":"Scoring higher the second time around: meta\u2010analyses of practice effects in neuropsychological assessment","volume":"26","author":"Calamia M","year":"2012","journal-title":"Clin Neuropsychol"},{"issue":"2","key":"e_1_2_10_72_1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.14802\/jmd.17067","article-title":"Prospective characterization of cognitive function in typical and \u2018brainstem Predominant'Progressive supranuclear palsy phenotypes","volume":"11","author":"Lee YC","year":"2018","journal-title":"J Mov Disord"},{"issue":"10","key":"e_1_2_10_73_1","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/mds.28274","article-title":"Brief clinical rating scales should not Be overlooked","volume":"35","author":"Lim SY","year":"2020","journal-title":"Mov Disord"},{"issue":"7","key":"e_1_2_10_74_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.55.7.934","article-title":"Fatigue and declines in cognitive functioning in multiple sclerosis","volume":"55","author":"Krupp LB","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"e_1_2_10_75_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1191\/1352458503ms946oa","article-title":"Cognitive fatigue during a test requiring sustained attention: a pilot study","volume":"9","author":"Schwid SR","year":"2003","journal-title":"Mult Scler"},{"issue":"3","key":"e_1_2_10_76_1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1518\/001872008X312152","article-title":"Vigilance requires hard mental work and is stressful","volume":"50","author":"Warm JS","year":"2008","journal-title":"Hum Factors"},{"issue":"6","key":"e_1_2_10_77_1","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s00415-019-09261-9","article-title":"Sustained attention failures on a 3\u2010min reaction time task is a sensitive marker of dementia","volume":"266","author":"Manuel AL","year":"2019","journal-title":"J Neurol"},{"issue":"3","key":"e_1_2_10_78_1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/mds.30112","article-title":"Prospective multicenter evaluation of the MDS \u201csuggestive of PSP\u201d diagnostic criteria","volume":"40","author":"Quattrone A","year":"2025","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_2_10_79_1","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2666-7568(23)00019-3","article-title":"The prevalence, correlation, and co\u2010occurrence of neuropathology in old age: harmonisation of 12 measures across six community\u2010based autopsy studies of dementia","volume":"4","author":"Nichols E","year":"2023","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"e_1_2_10_80_1","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1038\/s41467-024-52299-1","article-title":"Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer's disease","volume":"15","author":"Collij LE","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"e_1_2_10_81_1","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of Lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti C","year":"2023","journal-title":"Nat Med"},{"issue":"7","key":"e_1_2_10_82_1","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age\u2010related and APOE4\u2010associated","volume":"141","author":"Robinson JL","year":"2018","journal-title":"Brain"},{"issue":"6","key":"e_1_2_10_83_1","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/s41591-026-04398-3","article-title":"A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism","volume":"32","author":"Martinez\u2010Valbuena I","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"e_1_2_10_84_1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jalz.2019.06.4956","article-title":"New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures","volume":"16","author":"Boxer AL","year":"2020","journal-title":"Alzheimers Dement"},{"key":"e_1_2_10_85_1","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1210974","article-title":"Digital endpoints in clinical trials of Alzheimer's disease and other neurodegenerative diseases: challenges and opportunities","volume":"14","author":"Brem AK","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"e_1_2_10_86_1","doi-asserted-by":"crossref","DOI":"10.1002\/dad2.12423","article-title":"Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research","volume":"15","author":"Taylor JC","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"e_1_2_10_87_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.4266","article-title":"Reliability and validity of smartphone cognitive testing for frontotemporal lobar degeneration","volume":"7","author":"Staffaroni AM","year":"2024","journal-title":"JAMA Netw Open"},{"key":"e_1_2_10_88_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.parkreldis.2022.01.004","article-title":"Prediagnostic progressive supranuclear palsy \u2013 insights from the UK biobank","volume":"95","author":"Street D","year":"2022","journal-title":"Parkinsonism Relat Disord"},{"issue":"11","key":"e_1_2_10_89_1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/archneur.1988.00520350032011","article-title":"Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease","volume":"45","author":"Dubois B","year":"1988","journal-title":"Arch Neurol"},{"issue":"5","key":"e_1_2_10_90_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/13524585251329035","article-title":"Long\u2010term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosis","volume":"31","author":"Merlo D","year":"2025","journal-title":"Mult Scler"},{"issue":"20","key":"e_1_2_10_91_1","doi-asserted-by":"crossref","first-page":"e2020","DOI":"10.1212\/WNL.0000000000012850","article-title":"Association between cognitive trajectories and disability progression in patients with relapsing\u2013remitting multiple sclerosis","volume":"97","author":"Merlo D","year":"2021","journal-title":"Neurology"},{"key":"e_1_2_10_92_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102212","article-title":"The MSReactor computerized cognitive battery correlates with the processing speed test in relapsing\u2013remitting multiple sclerosis","volume":"43","author":"Yam C","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"e_1_2_10_93_1","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419859183","article-title":"The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis","volume":"12","author":"Merlo D","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"e_1_2_10_94_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/acn3.70015","article-title":"Longitudinal trajectories of digital cognitive biomarkers for multiple sclerosis","volume":"12","author":"Foong YC","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"e_1_2_10_95_1","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jalz.2010.12.009","article-title":"Intraindividual cognitive decline using a brief computerized cognitive screening test","volume":"8","author":"Darby DG","year":"2012","journal-title":"Alzheimers Dement"},{"issue":"9","key":"e_1_2_10_96_1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1017\/S1041610211000354","article-title":"Using cognitive decline in novel trial designs for primary prevention and early disease\u2010modifying therapy trials of Alzheimer's disease","volume":"23","author":"Darby D","year":"2011","journal-title":"Int Psychogeriatr"}],"container-title":["Movement Disorders Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mdc3.70847","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mdc3.70847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:01:18Z","timestamp":1791540078000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mdc3.70847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":95,"alternative-id":["10.1002\/mdc3.70847"],"URL":"https:\/\/doi.org\/10.1002\/mdc3.70847","archive":["Portico"],"relation":{},"ISSN":["2330-1619","2330-1619"],"issn-type":[{"value":"2330-1619","type":"print"},{"value":"2330-1619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2026-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"mdc3.70847"}}